Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

21.57 -1.95 (-8.27%)
Streaming Delayed Price Updated: 3:31 PM EDT, Jun 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38. 
Via Benzinga
Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May
Via Benzinga
Exposures Fossil Fuels
This Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
AnaptysBio Stock Jumps On Promising Rheumatoid Arthritis Drug Readout; Retail Traders Brace For Potential Offering
The company reported successful mid-stage results for its rheumatoid arthritis drug rosnilimab, which matched the efficacy of JAK inhibitors with fewer side effects. 
Via Stocktwits
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
From AnaptysBio, Inc.
Via GlobeNewswire
Beyond The Numbers: 5 Analysts Discuss AnaptysBio Stock
Via Benzinga
Where AnaptysBio Stands With Analysts
Via Benzinga
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
Forecasting The Future: 6 Analyst Projections For AnaptysBio
Via Benzinga
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Analyst Expectations For AnaptysBio's Future
Via Benzinga
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
Crude Oil Gains 1%; US Composite PMI Surges In March
Via Benzinga
Exposures Fossil Fuels
Intuitive Machines Posts Q4 Results, Joins Tesla, AnaptysBio, Coherent And Other Big Stocks Moving Higher On Monday
Via Benzinga
Anaptys Announces Stock Repurchase Plan
From AnaptysBio, Inc.
Via GlobeNewswire
UiPath Posts Weak Revenue, Joins SentinelOne, American Eagle And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Participation in March Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment
AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment. 
Via Investor's Business Daily
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
From AnaptysBio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
From AnaptysBio, Inc.
Via GlobeNewswire
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
From AnaptysBio, Inc.
Via GlobeNewswire
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.